Denosumab News and Research

RSS
Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone.
Study compares efficacy and side effects of popular osteoporosis drugs

Study compares efficacy and side effects of popular osteoporosis drugs

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients

IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Xgeva receives FDA approval for treating giant cell tumor of the bone

Xgeva receives FDA approval for treating giant cell tumor of the bone

Denosumab associated with improved overall survival in NSCLC patients

Denosumab associated with improved overall survival in NSCLC patients

Denosumab gives FREEDOM to heal fractures

Denosumab gives FREEDOM to heal fractures

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Denosumab effective in treating giant-cell tumor of the bone

Denosumab effective in treating giant-cell tumor of the bone

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Study: Breast cancer in young women is enriched with aggressive basal-like tumors

Study: Breast cancer in young women is enriched with aggressive basal-like tumors

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

Four new drugs can extend survival and prognosis of prostate cancer

Four new drugs can extend survival and prognosis of prostate cancer

FDA reviews Amgen’s prostate cancer drug Xgeva

FDA reviews Amgen’s prostate cancer drug Xgeva

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Exelixis reports cabozantinib phase 2 trial data on bone metastases

NCKU research team discovers potential target to treat osteoporosis

NCKU research team discovers potential target to treat osteoporosis

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011